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Summary
Background: Human papillomaviruses (HPVs) play an obligatory role in cervical cancer devel-
opment. Thus, immunization of women using a prophylactic vaccine against the most common
high-oncogenic risk types (e.g., HPV 16 and 18) and HPV 6 and 11, which contribute to de-
velopment of low-grade cervical lesions and cause most anogenital warts, represents a logical
primary prevention strategy.
Perspectives:, At the time of licensure, Phase II/Phase III studies showed that administration of a
quadrivalent HPV (types 6, 11, 16, 18) vaccine to young women (16 to 26 years) naïve to the vac-
cine HPV types resulted in 100% efficacy against HPV 16- and 18-related precancerous cervical
lesions, 100% efficacy against HPV 16- and 18-related high-grade vulvar/vaginal neoplasias, 95%
efficacy against HPV 6, 11, 16, or 18-related cervical intraepithelial neoplasia/adenocarcinoma
in situ, and 99% efficacy against HPV 6, 11, 16, or 18-related genital lesions. The quadrivalent
HPV vaccine is highly immunogenic in adolescent males and females, and long-term follow up
of young women did not detect evidence of waning immunity through 5 years.
Conclusions: The quadrivalent vaccine is generally well tolerated. The efficacy and safety of
the quadrivalent vaccine is continuing to be investigated in young men and mid-adult women.
Nordic cancer registries are providing ongoing long-term pharmacovigilance.
© 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Introduction
Human papillomaviruses (HPV) infections, which are very
common among sexually active women1,2, are linked not
only to development of genital neoplasias, such as cervi-
cal, vulvar, vaginal cancers, but also to high-grade (cervical
intraepithelial neoplasias [CIN] 2/3) and low-grade cervi-
cal lesions (CIN 1), anogenital warts, and vulvar/vaginal
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dysplasia.3- 9 Recent worldwide estimates indicate that
HPV-related infection causes 470,000 cases of cervical
cancer and claims the lives of about 250,000 women per
year,3,10 a large proportion of which occurs in developing
countries, where cervical screening programs using the
Papanicolaou (Pap) test are limited or absent.
In light of the central and obligatory role that HPV plays
in the development of cervical cancer, immunization of
women using a vaccine directed against the most common
high-oncogenic risk HPV types (e.g., HPV 16 and 18) repre-
sents a logical primary prevention strategy to reduce the
occurrence of this devastating disease.
The purpose of this article is to review the clinical
development, efficacy and safety results for a recombinant
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quadrivalent HPV vaccine in young women and adolescent
males and females, and to describe ongoing clinical trials
evaluating its efficacy in young men and mid-adult women
(26---45 years of age). The focus of the article is on clinical
efficacy in terms of preventing clinical disease caused by
HPV 6, 11, 16, and 18. For a detailed review of the ability
of quadrivalent vaccine to induce high, persistent anti-HPV
titers in young women and in male and female adolescents,
the reader is directed to the article on immunogenicity by
Dr. Frazer (this supplement).
Rationale for developing and composition of a
quadrivalent HPV L1 VLP vaccine
As reviewed in detail in the article by Dr. Paavonen (this
supplement), most HPV-related disease can be attributed
to HPV types 6, 11, 16, and 18. HPV types 6 and 11
are linked to development of nearly 90% of all anogenital
warts in women and men11 and approximately 10% of
low-grade cervical lesions.12 HPV 16 and 18 are responsible
for approximately 70% of cervical cancers, 70% of other
genital cancers in women, and approximately 85% of anal
cancers.7,13- 16 In addition, HPV 16 and 18 are associated
with approximately 25% of low-grade cervical lesions and
50% of high-grade cervical lesions.12,14 Men develop anal
or genital lesions related to HPV 16 and 18, and also con-
tribute to the risk of cervical cancer in their partners by
serving as carriers or vectors of HPV.16,17 Immunizing both
women and men, therefore, with a prophylactic quadriva-
lent HPV vaccine targeting these common, major HPV types
will result in substantial reductions in acquisition of HPV
infection and the global burden of HPV-related disease.
The quadrivalent vaccine comprises a mixture of 4 types
of virus-like particles (VLPs) derived from the major capsid
protein L1 of HPV 6, 11, 16, and 18. These type-specific
L1 VLPs are generated in culture using recombinant tech-
Figure 1 Quadrivalent HPV vaccine clinical program (2003 onward)
nology in the yeast Saccharomyces cerevisiae, and after
purification, are adsorbed onto the adjuvant amorphous
aluminum hydroxyphosphate sulfate.18 The quadrivalent
vaccine is administered by intramuscular injection (0.5
mL injection volume containing 225 µg of aluminum ad-
juvant) in three doses within 6 months (day 1, month 2,
and month 6). Yeast-derived vaccines have been success-
fully employed to produce many other vaccines, including
hepatitis B vaccine, and have been generally safe and
well-tolerated when administered to millions of children
and adults worldwide.
Quadrivalent HPV vaccine clinical
development program
As summarized in Figure 1, the quadrivalent HPV vaccine
clinical development program is comprehensive and, to
date, has involved the participation of more than 30,000
subjects in 33 countries. The goal was to include sub-
jects with a broad range of ethnic backgrounds, sexual
behaviors, and concomitant diseases, thereby allowing
generalization to the overall population. Two Phase II
studies, both in women 16---23 years of age, have been
conducted, including a proof-of-principle study evaluating
a monovalent HPV 16 vaccine19,20 and a dose-ranging study
(protocol 007) of the quadrivalent vaccine.18 Follow up of
women in the latter study was extended beyond the initial
design of 36 months, permitting efficacy evaluation up to 5
years after the first immunization.21
Data from two ongoing, randomized, double-blind,
placebo-controlled, multicenter Phase III studies have
been evaluated (approximately two years of follow-up at
the time of licensure): the Females United to Unilaterally
Reduce Endo/Ectocervical disease (FUTURE I) and FUTURE
II.22,23 In total, these phase III studies enrolled more than
17,000 nonpregnant young women (16 to 23 years of age)
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and plan to include follow up visits over a period of 4
years. The studies evaluated the efficacy of a quadrivalent
vaccine in reducing the incidence of HPV 6-, 11-, 16- and
18-related CIN 1, CIN 2/3, vulvar intraepithelial neopla-
sia (VIN), vaginal intraepithelial neoplasia (VaIN), vaginal
cancer, vulvar cancer, AIS, cervical cancer, and external
genital warts. In addition, the duration of vaccine efficacy
beyond the planned end of the primary efficacy trial is
being extended in a subset of women enrolled in the Nordic
region (Nordic Cancer Registry Extension).
An additional Phase III study that has been completed
compared the immunogenicity and tolerability of a quadri-
valent HPV vaccine in adolescent boys and girls to those
in women 16---23 years of age.24 This study showed that
higher anti-HPV (types 6, 11, 16, and 18) antibody levels
occurred in adolescent males and females compared with
adult women and supported bridging the efficacy findings
from older adolescents and young adult women to young
adolescents. Further discussion of this study can be found
in the review by Dr Frazer (this supplement). Two addi-
tional Phase III studies were initiated in 2004 (due to be
completed in 2009) in order to evaluate the efficacy of the
quadrivalent vaccine in mid-adult women 26---45 years and
in 16---23 old males.
Choice of appropriate clinical endpoint to
evaluate HPV vaccine efficacy in preventing
cervical cancer
A key aspect of the clinical efficacy studies of prophylactic
HPV vaccines in women has been the utilization of CIN
2/3 as a surrogate marker for cervical cancer. While the
primary goal of any HPV vaccine is to reduce the occur-
rence of cervical cancer, ethical, sample size, and time
considerations make it imperative to use an appropriate
and meaningful surrogate endpoint for clinical efficacy
evaluations.
Several clinical conditions could potentially serve as sur-
rogate endpoints, including persistent HPV infection, CIN 1,
and CIN 2/3. However, only cervical biopsy-confirmed CIN
2/3 meets all of the key criteria for a robust, reliable, and
clinically relevant endpoint to test HPV vaccine efficacy.
This is because: 1) CIN 2/3 is an obligate precursor for,
and is closely temporally associated with, the development
of cervical cancer; 2) CIN 2/3 is a clinically important
syndrome requiring treatment; and 3) a reduction in in-
cidence of CIN 2/3 implies a reduced risk of cervical
cancer. Thus, expert committees convened by the World
Health Organization and the United States Food and Drug
Administration recommended that CIN 2/3 be employed as
the definitive endpoint to measure the efficacy of an HPV
vaccine efficacy.25
Efficacy of a quadrivalent HPV vaccine
Phase II dose-ranging study
A double-blinded, placebo-controlled, dose-ranging study
of the quadrivalent vaccine was conducted in 1,106 women
16---23 years of age with the objective of guiding dose
selection for subsequent Phase III studies and to determine
efficacy in preventing persistent HPV infection and disease
related to HPV 6, 11, 16, and 18.18 Women naïve to the
relevant HPV type at baseline received in a randomized
manner 1 of 3 preparations of the quadrivalent vaccine or
placebo, administered by intramuscular injection at Day 1,
Month 2, and Month 6. The following doses for the HPV
vaccine were used:
Group 1: 20 µg type 6, 40 µg type 11, 40 µg type 16, and
20 µg type 18;
Group 2: 40 µg type 6, 40 µg type 11, 40 µg type 16, and
40 µg type 18;
Group 3: 80 µg type 6, 80 µg type 11, 40 µg type 16, and
80 µg type 18.
An interim safety and immunogenicity analysis used as
the primary end point the type-specific immune response
at Month 7, corresponding to approximately the peak
anti-HPV responses, showed that the lowest vaccine dose
induced serological antibody responses comparable to the
intermediate-dose and high-dose preparations. Following
the interim analysis, the study focused on evaluating the
efficacy of the low-dose formulation, which was ultimately
chosen for Phase III studies.
In women who received the quadrivalent vaccine, the
combined incidence of persistent HPV 6, 11, 16, or 18
infection or related cervical and genital disease over the
30 months of follow-up was decreased by 90% (95% CI,
71---97%) compared with women receiving placebo. Con-
sidering CIN and genital warts as a single endpoint, the
quadrivalent vaccine was 100% effective (P = 0.0151) in
HPV-naïve women. None of the patients receiving vaccine
and 6 patients receiving placebo developed HPV 6-, 11-,
16-, or 18-related cervical and genital disease over 30
months. The high efficacy of the vaccine was sustained
over 5 years, as evidenced by an extended follow up of 241
patients.21 At 5 years, the vaccine prevented 96% or 100%
of HPV 6, 11, 16, or 18 infection or cervical and genital
disease, respectively (Table 1).21 These findings demon-
strate that a quadrivalent vaccine substantially reduces
the acquisition of infection and clinical disease caused by
these common HPV types with an efficacy similar to that
with currently available vaccines, including the polyvalent
pneumococcal vaccine and polio vaccines.26,27
All women receiving quadrivalent vaccine developed
detectable neutralizing antibodies to HPV 6, 11, 16, and
18 at completion of the vaccine regimen at Month 7 (see
review by Dr. Frazer). Geometric mean titers of vaccine-
induced antibodies peaked at Month 7 and thereafter
gradually declined, reaching a plateau at Month 24. In
addition, women vaccinated with the quadrivalent vaccine
exhibited immune memory at five years of follow-up, as
demonstrated by a marked anamnestic response.28
Combined Phase II/III analysis
To further define the efficacy of the quadrivalent vaccine
efficacy against HPV-related external genital lesions, a
combined Phase II and III efficacy analysis was performed
that involved more than 20,000 women ranging in age from
16 to 26 years and spanned Europe, North America, Latin
America and Asia Pacific region.29,30 Table 2 summarizes
the principal design features of studies included in the
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Table 1 Per-protocol efficacy results from a Phase II study (Protocol 007) comparing quadrivalent (HPV types 6, 11, 16, and
18) vaccine with placebo (all subjects through 3 years and extension subjects over 5 years). Data extracted from Villa et al.21
HPV 6, 11, 16 or 18-related Quadrivalent vaccine Placebo Efficacy 95% CI
(N = 277) (N = 275)
N Cases N Cases
Infection 235 2 * 233 45 95.6% (83.3, 99.5)
Disease 235 0 233 6 100% (12.4, 100)
CIN 1, 2 or 3 235 0 233 3 100% (<0, 100)
Condyloma 235 0 233 3 100% (<0, 100)
A subset (241 subjects) had follow-up through 5 years post-dose 1.
* 1 case of confirmed persistent infection: HPV 18 DNA detected at months 12 and 18 only. 1 case of HPV 16 DNA detected at the last
visit (month 36).
Table 2 Design overview of principal studies evaluating the safety and efficacy of a quadrivalent vaccine in young women
Design feature Villa et al. 2005
(Protocol 007)18
FUTURE I22 FUTURE II23
Sample size 550 5,746 12,157
Study sites International, multicenter
Blinding Double-blind
Study vaccine Quadrivalent vaccine or placebo
Vaccination regimen 0, 2, 6 mos
Visit schedule after vaccination Every 6 mos for 3 yrs Every 6 mos, for 4 years Yearly for 4 years
Age 16---23 yrs 16---23 yrs 15---26 yrs
Number of lifetime male sex partners 0 to 4
Previous history of HPV-related disease Not allowed
Cytological abnormalities or HPV infection
at enrollment
Allowed
Subjects with visible genital warts were not enrolled
Requirement for biopsy All abnormal areas
Pathology interpretation Routine in central lab; endpoint determined by blinded expert pathology panel
HPV causality assessment PCR assay on frozen biopsy specimens
Protocol 005 results20 involving 2391 16---23-year-old women were also included in HPV 16 specific results.
combined analysis (i.e., FUTURE I and II as well as Phase
II protocol 007). In addition, results from protocol 005,20
which involved immunization of 2391 women, 16---23 year-
old, with a monovalent HPV 16 L1 VLP vaccine, were also
included in the HPV 16-specific results. The combined data
presented in this review is based on an analysis conducted
at the time of vaccine licensure (i.e., approximately 2
years of post-vaccination follow-up). These values differ
slightly from the final published combined analyses, which
presents 3-year data.
The primary analytical end point was the combined
incidence of HPV 16/18-related CIN 2/3, AIS, or cancer (as
determined by a study pathology panel that was blinded
to HPV DNA results and vaccine allocation). This primary
analysis involved the per-protocol population --- that is,
subjects who had no serum antibodies to HPV 16 or 18 at
day 1, had no HPV 16 or 18 DNA in their swabs at day
1 through month 7, and had completed 3 vaccinations).
However, additional, prespecified secondary analyses were
performed utilizing a modified intention-to-treat popula-
tion --- that is, women who received ≥1 dose of vaccine and
were HPV 16/18 negative at day 1. This population more
closely resembles real-life settings than the rigidly defined
per protocol cohort.
Overall, 73% of enrolled women on day 1 tested negative
for HPV types 6, 11, 16, 18 and 27% tested positive to at
least one HPV type. The relative prevalence rates per HPV
type occurred in the order HPV 16 > HPV 6 > HPV 18 > HPV
11, a finding generally consistent with epidemiologic data.
The two study groups (quadrivalent vaccine and placebo)
were similar with respect to HPV-associated disease at
baseline regardless of the type of analysis performed
(per protocol or modified intention-to-treat). As shown in
Table 3, approximately 11% of both study groups had a
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Table 3 Abnormal cervical cytology at enrollment in the combined Phase II and III analysis of efficacy studies
Day 1 Pap test diagnosis Quadrivalent vaccine Placebo
(N = 9087) (N = 9087)
Any cytological abnormality 11.5% 11.3%
ASCUS 4.5% 4.7%
ASC-H 0.3% 0.3%
LSIL 5.9% 5.7%
HSIL 0.7% 0.5%
AGC 0.066% 0.03%
ASCUS = atypical squamous cell of unknown significance, ASC-H = atypical squamous cells --- cannot exclude HSIL, LSIL = low-grade
squamous intraepithelial neoplasia, HSIL = high-grade squamous intraepithelial neoplasia, AGC = atypical glandular cells.
% based on number of subjects with indicated diagnosis/number of subjects with a satisfactory Day 1 Pap test result multiplied by 100.
cytological abnormality at baseline, the vast majority of
which could be categorized as LSIL or ASCUS.
At the time of licensure, in young women naïve to
HPV 16 and 18 until completion of the vaccination regi-
men, the combined Phase II/Phase III per-protocol analysis
demonstrated that prophylactic quadrivalent HPV vaccina-
tion was 100% efficacious against high-grade precancerous
and noninvasive cancerous cervical lesions related to HPV
16 and 18 (Figure 2). This analysis also showed that the
quadrivalent vaccine prevented 100% of HPV 16- and HPV
18-related cases of high-grade (grade 2/3) vulvar or vaginal
neoplasias, 95.2% of HPV 6, 11, 16, or 18-related cases of
CIN (grades 1, 2/3) or AIS and 99.1% of HPV 6, 11, 16, or
18-related cases of genital lesions, including genital warts
and vulvar or vaginal neoplasias (Figure 2).29,30
Similarly, in the modified intention-to-treat cohort, a
broader group that included all of the women in the per
protocol group plus women who became infected with HPV
16 or HPV 18 during the vaccination period or who violated
the protocol by missing some protocol visits or vaccine
doses, the quadrivalent vaccine was still 98.8% efficacious
against high-grade precancerous and noninvasive cancerous
cervical lesions related to HPV 16 and 18 (Figure 2). In
addition, the quadrivalent vaccine prevented 100% of HPV
16- and HPV 18-related cases of high-grade (grade 2/3)
vulvar or vaginal neoplasias, 93.7% of HPV 6, 11, 16, or
18-related cases of CIN (grades 1, 2, 3) or AIS and 94.8%
of HPV 6, 11, 16, or 18-related cases of genital lesions
including genital warts and vulvar or vaginal neoplasias
(Figure 2).
The combined Phase II/III study population at baseline
included women who were naïve to HPV 6, 11, 16, and
18 as well as women who had been previously exposed
to these specific types, as determined by serology testing
for presence of HPV type-specific antibodies or polymerase
chain reaction (PCR) testing of genital samples for the
presence of HPV DNA. Thus, it is possible to examine broad
trends in efficacy in preventing HPV 6/11/16/18-related
disease in several groups of patients categorized according
to whether they were HPV DNA positive by PCR or seropos-
itive to the particular vaccine HPV types at baseline. The
quadrivalent vaccine was 100% effective in reducing the
incidence of HPV 6/11/16/18-related disease in HPV-naïve
women (i.e., seronegative and HPV DNA negative by PCR)
as well as in women who had been previously exposed to at
least 1 vaccine HPV type at enrollment, but had no ongoing
HPV infection (i.e., seropositive but HPV DNA negative by
PCR). However, there was no clear evidence of protection
from disease cause by HPV types for subjects that were
HPV DNA positive by PCR and/or seropositive at baseline.31
Safety
The combined quadrivalent HPV vaccine safety database
indicated that the quadrivalent vaccine was generally
well tolerated in both young women and adolescents, as
assessed using vaccination-report card (VRC)-aided surveil-
lance for 14 days following each vaccine injection (Ta-
ble 4).32 The most common vaccine- or placebo-related
systemic adverse experiences were fever (10.3% vs 8.6%),
nausea (4.2% vs 4.1%), and dizziness (2.8% vs 2.6%), re-
spectively (Table 4). Vaccine-related injection site adverse
experiences included pain swelling, erythema, and pruri-
tus, all of which occurred at a somewhat higher frequency
than in subjects receiving aluminum-containing placebo
(Table 4). Serious adverse experiences were reported in
102 of 21,464 total subjects who received both quadri-
valent vaccine and placebo (including 9---26-year-old girls
and women and 9---15-year-old boys). The most frequently
reported serious adverse experiences in subjects receiving
quadrivalent vaccine and placebo were headache (0.03%
vs 0.02%, respectively), gastroenteritis (0.03% vs 0.01%),
appendicitis (0.02% vs 0.01%), and pelvic inflammatory
disease (0.02% vs 0.01%), but none was considered to be
related to vaccine components.32
Adverse event data from the Phase III adolescent
immunogenicity substudy showed that the quadrivalent
vaccine was generally well tolerated in young adolescent
girls or boys, as well as in older adolescent and young
adult females.24 All systemic adverse events and vaccine-
related systemic events occurred with a similar frequency
in these groups. The younger groups (boys and girls aged
10 to 15 years) had slightly fewer injection site adverse
reactions compared with adult women, although febrile
episodes (oral temperature ≥37.7°C) over the first 15 days
following vaccine administration occurred more often in
boys and girls than in young women aged (12.8---13.8%
vs. 7.3%, respectively).24 However, these fevers resolved
quickly without any complications.
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Figure 2 Combined analysis (per-protocol [top] and modified intention-to-treat [bottom]) of Phase II and III clinical studies at the time
of vaccine licensure comparing effects of quadrivalent HPV vaccine with placebo on the occurrence of high-grade precancerous genital
lesion or adenocarcinoma in situ and external genital lesions (vulvar, vaginal intraepithelial neoplasia and genital warts) in young women.
Percentage reductions are shown with 95% CI in parentheses. The first endpoint (HPV16/18-related CIN 2/3 or AIS) included data from
protocol 005 (monovalent vaccine), protocol 007, and FUTURE I and II; all other endpoints included protocol 007, FUTURE I and II only.
CIN = cervical intraepithelial neoplasia, VIN = vulvar intraepithelial neoplasia, AIS = adenocarcinoma in situ, VaIN = Vaginal intraepithelial
neoplasia
Evaluation of pregnancy outcomes included the medical
history during the pregnancy, mother and child' s outcomes
in the neonatal period, causes of spontaneous abortion,
and elective termination. Infants were followed to the
end of studies to look for late events not detected in the
neonatal period. At the time of licensure, a total of 2266
subjects became pregnant during clinical trials (vaccine
= 1115, placebo = 1151), even though subjects were in-
structed to use contraception during the vaccination phase
of the study. Of these pregnancies, the percentage of
subjects experiencing an adverse outcome was compara-
ble in the vaccine or placebo groups. The proportion of
pregnant women experiencing a serious adverse experi-
ence (the most common being premature onset of labor,
conditions resulting in Caesarean section, and pregnancy-
related medical problems) was also 3.6% in both groups.
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Table 4 Vaccine-related injection site and systemic clinical adverse experience summary in the integrated quadrivalent HPV
vaccine safety database *
Systemic adverse experience Quadrivalent vaccine Placebo
(1---15 days postvaccination) (N = 5088) (N = 3790)
Fever 10.3% 8.6%
Nausea 4.2% 4.1%
Dizziness 2.8% 2.6%
Injection site adverse experience Quadrivalent vaccine Aluminium-containing placebo Saline placebo
(1---5 days postvaccination) (N = 5088) (N = 3470) (N = 320)
Pain 83.9% 75.4% 48.6%
Swelling 25.5% 15.8% 7.3%
Erythema 24.6% 18.4% 12.1%
Pruritis 3.1% 2.8% 0.6%
* Vaccine-related adverse experiences include only those occurring at a frequency of ≥1% among recipients of quadrivalent vaccine
and also at a greater frequency compared with placebo recipients.
Data from Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine. Prescribing Information.32
The rates of congenital abnormalities were comparable to
those in the general population and similar between the
quadrivalent HPV vaccine (15 cases) and the placebo group
(16 cases). However, it is recommended that pregnancy
be avoided during the course of vaccination. Through
the central Nordic registry, long-term efficacy and safety
is continuing to be evaluated on a population basis in
real time and will include monitoring general safety and
pregnancy outcomes.
Ongoing studies with quadrivalent HPV
vaccine
An ongoing study in the Phase III clinical development
program for the quadrivalent HPV vaccine is evaluating
the immunogenicity and tolerability of the vaccine in men
16 to 23 years old; results are expected towards the end
of 2007. Genital warts occur in both sexually active men
and women, and a majority (85%) of anal cancer cases
worldwide can be attributed to HPV infection.7 Thus, it is
appropriate to investigate the potential impact and bene-
fits of administering a quadrivalent HPV vaccine in males.33
This is particularly germane in light of the lack of suc-
cess of other vaccination programs that targeted females
only. For example, selective immunization of schoolgirls,
susceptible women after pregnancy, and women at special
risk had limited success in preventing rubella-induced mal-
formations; in contrast, a program immunizing both boys
and girls at the ages of 18 months and 12 years against
measles, mumps, rubella vaccination (MMR) ultimately led
to complete eradication of the rubella syndrome.34
An additional Phase III study is being conducted in
mid-adult women aged 24 to 45 years of age. This placebo-
controlled, triple-blinded study is following a total of 2800
subjects over a 3-year period (with Pap screening, HPV DNA
testing, and genital inspections every 6 months) in order to
evaluate the safety profile of the quadrivalent vaccine and
its efficacy in preventing HPV types 6-, 11-, 16-, and 18-
related infections and disease. This is an important study
since women remain at risk of HPV infection throughout
their life.
Conclusions
The quadrivalent (HPV types 6, 11, 16, 18) vaccine is
formulated to protect against the most common disease-
causing HPV types and is expected to reduce substantially
the morbidity, mortality, and cost burden of HPV infection.
The quadrivalent vaccine has demonstrated high efficacy in
HPV-naïve women against anogenital cancers by preventing
HPV 16/18-related CIN 3/AIS (cervical cancer), HPV 16/18-
related VIN 2/3 and VaIN 2/3 (vulvar/vaginal cancer), CIN
(all grades), as well as external genital lesions (VIN, VaIN
and genital warts) caused by HPV types 6, 11, 16, 18.
In adolescent males and females, and young women the
quadrivalent HPV vaccine was found to be immunogenic
and safe, with a tolerability profile comparable to placebo.
Long-term follow up of young women provide no evidence
of waning immunity through 5 years, as evidenced by
high efficacy for prevention of persistent infection and
disease caused by HPV 6, 11, 16 or 18. Based on these
very positive results, more than 60 countries, including
the United States and European Union, have approved
the quadrivalent vaccine for clinical use. As part of the
Phase III clinical development program, the efficacy and
safety of the quadrivalent HPV vaccine is continuing to be
investigated in young men and mid-adult women.
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